Literature DB >> 26482044

Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.

Laura H Tang1, Brian R Untch2, Diane L Reidy3, Eileen O'Reilly3, Deepti Dhall4, Lily Jih4, Olca Basturk5, Peter J Allen2, David S Klimstra5.   

Abstract

PURPOSE: Most well-differentiated neuroendocrine tumors (WD-NET) of the enteropancreatic system are low-intermediate grade (G1, G2). Elevated proliferation demonstrated by either a brisk mitotic rate (>20/10 high power fields) or high Ki-67 index (>20%) defines a group of aggressive neoplasms designated as high-grade (G3) neuroendocrine carcinoma (NEC). High-grade NEC is equated with poorly differentiated NEC (PD-NEC) and is associated with a dismal outcome. Progression of WD-NETs to a high-grade neuroendocrine neoplasm very rarely occurs and their clinicopathologic and molecular features need to be characterized. EXPERIMENTAL
DESIGN: We investigated 31 cases of WD-NETs with evidence of a component of a high-grade neoplasm. The primary sites included pancreas, small bowel, bile duct, and rectum. Histopathology of the cases was retrospectively reviewed and selected IHC and gene mutation analyses performed.
RESULTS: The high-grade component occurred either within the primary tumor (48%) or at metastatic sites (52%). The clinical presentation, radiographic features, biomarkers, and the genotype of these WD-NETs with high-grade component remained akin to those of G1-G2 WD-NETs. The median disease-specific survival (DSS) was 55 months (16-119 months), and 2-year and 5-year DSS was 88% and 49%, respectively-significantly better than that of a comparison group of true PD-NEC (DSS 11 months).
CONCLUSIONS: Mixed grades can occur in WD-NETs, which are distinguished from PD-NECs by their unique phenotype, proliferative indices, and the genotype. This phenomenon of mixed grade in WD-NET provides additional evidence to the growing recognition that the current WHO G3 category contains both WD-NETs as well as PD-NECs. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 26482044      PMCID: PMC4988130          DOI: 10.1158/1078-0432.CCR-15-0548

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Authors:  Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

Review 3.  Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Günter Klöppel
Journal:  Endocr Relat Cancer       Date:  2011-10-17       Impact factor: 5.678

Review 4.  The origin of neuroendocrine tumors and the neural crest saga.

Authors:  Juan Rosai
Journal:  Mod Pathol       Date:  2011-04       Impact factor: 7.842

Review 5.  The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.

Authors:  Ben Lawrence; Bjorn I Gustafsson; Mark Kidd; Marianne Pavel; Bernhard Svejda; Irvin M Modlin
Journal:  Endocrinol Metab Clin North Am       Date:  2011-03       Impact factor: 4.741

6.  Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.

Authors:  Laura H Tang; Mithat Gonen; Cyrus Hedvat; Irvin M Modlin; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

7.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

8.  Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?

Authors:  Jinru Shia; Laura H Tang; Martin R Weiser; Baruch Brenner; N Volkan Adsay; Edward B Stelow; Leonard B Saltz; Jing Qin; Ron Landmann; Gregory D Leonard; Deepti Dhall; Larissa Temple; Jose G Guillem; Philip B Paty; David Kelsen; W Douglas Wong; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2008-05       Impact factor: 6.394

9.  Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Authors:  Fritz-Line Vélayoudom-Céphise; Pierre Duvillard; Lydia Foucan; Julien Hadoux; Cecile N Chougnet; Sophie Leboulleux; David Malka; Joël Guigay; Diane Goere; Thierry Debaere; Caroline Caramella; Martin Schlumberger; David Planchard; Dominique Elias; Michel Ducreux; Jean-Yves Scoazec; Eric Baudin
Journal:  Endocr Relat Cancer       Date:  2013-08-19       Impact factor: 5.678

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  91 in total

Review 1.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

Review 2.  Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.

Authors:  Mohamad Bassam Sonbol; Thorvardur R Halfdanarson
Journal:  Curr Treat Options Oncol       Date:  2019-08-19

3.  Neuroendocrine tumours in 2016: Defining rules for increasingly personalized treatments.

Authors:  Massimo Falconi; Stefano Partelli
Journal:  Nat Rev Clin Oncol       Date:  2016-12-06       Impact factor: 66.675

4.  Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Chiara Liverani; Alberto Bongiovanni; Laura Mercatali; Federica Pieri; Chiara Spadazzi; Giacomo Miserocchi; Giandomenico Di Menna; Flavia Foca; Sara Ravaioli; Alessandro De Vita; Claudia Cocchi; Giulio Rossi; Federica Recine; Toni Ibrahim
Journal:  Endocr Pathol       Date:  2021-01-06       Impact factor: 3.943

Review 5.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

6.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889

7.  Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.

Authors:  Nitya Raj; Emily Valentino; Marinela Capanu; Laura H Tang; Olca Basturk; Brian R Untch; Peter J Allen; David S Klimstra; Diane Reidy-Lagunes
Journal:  Pancreas       Date:  2017-03       Impact factor: 3.327

8.  Grade 3 Neuroendocrine Tumor (G3 NET) in a Background of Multiple Serotonin Cell Neoplasms of the Ileum Associated with Carcinoid Syndrome and Aggressive Behavior.

Authors:  Francesca Capuano; Oneda Grami; Luigi Pugliese; Marco Paulli; Andrea Pietrabissa; Enrico Solcia; Alessandro Vanoli
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

Review 9.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

Review 10.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.